Business
Fresenius Medical Care Begins Broader U.S. Commercialization of 5008X™ CAREsystem, Achieves Key Milestones in Efforts to Introduce High-Volume Hemodiafiltration Dialysis Therapy to Individuals with Kidney Disease in the U.S.
Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today begins the second phase of the company's efforts to introduce high-volume hemodiafiltration (HVHDF) kidney replacement therapy across the United States. The company last week received FDA 510(k) clearance for the updated version of its new, hemodiafiltration-capable 5008X CAREsystem with additional features, a key benchmark enabling the next steps in the company's broade
About this update from Fresenius Medical Care Ag
[{"type":"list","items":[{"val":[{"type":"text","content":"Updated 5008X CAREsystem with Additional Features Receives FDA 510(k) Clearance","length":84,"tagName":"p"}]},{"val":[{"type":"text","content":"Company announces first wave of Fresenius Kidney Care clinics in the U.S. to begin offering high-volume hemodiafiltration therapy to dialysis patients","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"Introducing the 5008X CAREsystem and hemodiafiltration kidney replacement therapy is a key pillar of the company's growth strategy","length":139,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":384,"olType":false},{"type":"text","content":"BAD HOMBURG, Germany, June 4, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today begins the second phase of the company's efforts to introduce high-volume hemodiafiltration (HVHDF) kidney replacement therapy across the United States. The company last week received FDA 510(k) clearance for the updated version of its new, hemodiafiltration-capable 5008X CAREsystem with additional features, a key benchmark enabling the next steps in the company's broader commercialization efforts across the U.S. later this year, followed by a full-scale commercial launch in 2026.","length":680,"tagName":"p"},{"type":"image","alt":"Fresenius Medical Care (PRNewsfoto/Fresenius Medical Care North Am)","displaySize":"","headline":null,"caption":"Fresenius Medical Care (PRNewsfoto/Fresenius Medical Care North Am)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":86,"url":"https://media.zenfs.com/en/prnewswire.com/1ea334d2fed6b92c9bd382003cb7c081"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CAPs.jZA.Pm6wlpD_VdyoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE1MjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/1ea334d2fed6b92c9bd382003cb7c081","width":400,"height":86}},"href":"https://mma.prnewswire.com/media/655917/FMC_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Last week's FDA clearance of our updated 5008X CAREsystem with additional features was a critical milestone in our work to improve the lives of people living with kidney disease by bringing industry-leading, high-volume hemodiafiltration dialysis th...